gvtcx

Transitional Drugs 5

key details

Value£45,077,163 (£54,092,565 inc. VAT)
Statuscomplete
Category (CPV) 33600000
RegionWales
Deadline17 Nov 2025
Procedureopen
SME suitableYes
OCIDocds-h6vhtk-05a8e6

Awards (3)

This procurement was awarded to 3 suppliers. Values shown are per-award; the notice total is £45,077,163.

SupplierValueDateStatus
Janssen Ltd shared £5,577,339 25 Nov 2025 active
Mercury Pharmaceuticals Ltd shared £5,577,339 25 Nov 2025 active
Teva UK Ltd shared £5,577,339 25 Nov 2025 active

description

The provision of Drugs that have recently lost exclusivity

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

4 notices published against this procurement.

PublishedTypeRegimeNotice
6 Oct 2025 Preliminary market engagement (UK2) Procurement Act 2023 062588-2025
16 Oct 2025 Tender notice (UK4) Procurement Act 2023 066072-2025
8 Dec 2025 Contract award (UK6) Procurement Act 2023 080771-2025
29 Jan 2026 Contract details (UK7) Procurement Act 2023 007905-2026

more from NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.